trending Market Intelligence /marketintelligence/en/news-insights/trending/cEGJ9ZexYvsQVRF0FDRaQQ2 content
Log in to other products

Login to Market Intelligence Platform


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

Thank you for your interest in S&P Global Market Intelligence! We noticed you've identified yourself as a student. Through existing partnerships with academic institutions around the globe, it's likely you already have access to our resources. Please contact your professors, library, or administrative staff to receive your student login.

At this time we are unable to offer free trials or product demonstrations directly to students. If you discover that our solutions are not available to you, we encourage you to advocate at your university for a best-in-class learning experience that will help you long after you've completed your degree. We apologize for any inconvenience this may cause.

In This List

US FDA accepts Eli Lilly's application for nonopioid migraine treatment

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry


IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help

US FDA accepts Eli Lilly's application for nonopioid migraine treatment

The U.S. Food and Drug Administration accepted Eli Lilly and Co.'s Biologics License Application to review galcanezumab for the prevention of migraine in adults.

The application includes results from three phase 3 studies, where the medicine showed a statistically significant decrease in the average number of monthly migraine headache days compared to placebo.

Galcanezumab is submitted for use as a once-monthly, self-administered injection via auto-injector pen or prefilled syringe.

Galcanezumab represents the first of three investigational, nonopioid treatments being developed as part of Eli Lilly's overall pain portfolio. The portfolio also includes lasmiditan for the acute treatment of migraine and tanezumab, developed in partnership with Pfizer Inc., for the treatment of osteoarthritis, chronic low back pain and cancer pain.